Patents Assigned to SANGAMO THERAPEUTICS FRANCE
  • ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20240067732
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 27, 2023
    Publication date: February 29, 2024
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
    Patent number: 11814432
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 14, 2023
    Assignees: The University of British Columbia, Sangamo Therapeutics France
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR INTERLEUKIN-23 RECEPTOR
    Publication number: 20210380704
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 9, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, Julie Gertner-Dardenne, François Meyer
  • NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS
    Publication number: 20210292389
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof, and to an immune cell expressing said CAR. The present invention further relates to therapeutic methods comprising the administration of an immune cell expressing a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, David Fenard, Julie Gertner-Dardenne, François Meyer
  • NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20200283530
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li ZHOU, Tobias ABEL, François MEYER, Megan LEVINGS, Nicolas DAWSON, Caroline LAMARCHE